Do Pharmacogenomic Tests Provide Value to Policy Makers? Ya-Chen Tina ShihLajos Pusztai Editorial 25 November 2012 Pages: 1173 - 1177
Letter From the Commissioner’s Office at the US FDA John A. Vernon Editorial 25 November 2012 Pages: 1179 - 1179
Assessing Generalisability in Model-Based Economic Evaluation Studies Hege UrdahlAndrea MancaMark J. Sculpher Review Article 25 November 2012 Pages: 1181 - 1197
Generic Health-Related Quality-of-Life Assessment in Children and Adolescents Ulrike Ravens-SiebererMichael ErhartMonika Bullinger Review Article 25 November 2012 Pages: 1199 - 1220
Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis James R. SpaldingJoel Hay Original Research Article 25 November 2012 Pages: 1221 - 1232
Association of Co-Morbidities with Prescribing Patterns and Cost Savings Wei YuXinhua S. RenLewis E. Kazis Original Research Article 25 November 2012 Pages: 1233 - 1248
Candesartan Cilexetil Greg L. PloskerSusan J. Keam Adis Pharmacoeconomic Drug Evaluation 25 November 2012 Pages: 1249 - 1272
Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies Stuart Birks Correspondence 25 November 2012 Pages: 1273 - 1274
The Authors’ Reply J. M. BosM. J. PostmaL. Annemans Correspondence 25 November 2012 Pages: 1275 - 1276